| Keryx Biopharmaceuticals, Inc. to Host Conference Call on First Quarter 2010 ... - PharmaLive.com (press release) |
|
|
PharmaLive.com (press release)The Phase 3 clinical program of Zerenex in the treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease is being ...Keryx Biopharmaceuticals, Inc. - Financial And Strategic Analysis Review - New ... read more |